Long-term Efficacy of Platelet Glycoprotein IIb/IIIa Integrin Blockade With Eptifibatide in Coronary Stent Intervention
Authors:
- J. Conor O'SHeaJOJ. Conor O'SHea
- Christopher E. BullerCBChristopher E. Buller
- Warren J. CantorWCWarren J. Cantor
- A. Bleakley ChandlerACA. Bleakley Chandler
- Eric A. CohenECEric A. Cohen
- David J. CohenDCDavid J. Cohen
- Ian C. GilchristIGIan C. Gilchrist
- Neal S. KleimanNKNeal S. Kleiman
- Marino LabinazMLMarino Labinaz
- Mina MadanMMMina Madan
- Gail E. HafleyGHGail E. Hafley
- Robert M. CaliffRCRobert M. Califf
Open Access
- 6 February 2002
- journal article
- clinical trial
- Published by American Medical Association (AMA) in JAMA
- Vol. 287 (5) , 618-621
Abstract
Over the past decade, evidence has documented the efficacy of intravenous platelet glycoprotein (Gp) IIb/IIIa integrin blockade as an adjunct to percutaneous coronary intervention (PCI).1,2 Blockade of the Gp IIb/IIIa receptor reduces ischemic complications of PCI across all indications for PCI, among the various devices used for PCI, throughout a broad range of heparin anticoagulation strategies, and across several different agents.3-8Keywords
This publication has 5 references indexed in Scilit:
- Comparison of Two Platelet Glycoprotein IIb/IIIa Inhibitors, Tirofiban and Abciximab, for the Prevention of Ischemic Events with Percutaneous Coronary RevascularizationNew England Journal of Medicine, 2001
- Design and methodology of the ESPRIT trial: Evaluating a novel dosing regimen of eptifibatide in percutaneous coronary interventionAmerican Heart Journal, 2000
- Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trialThe Lancet, 1999
- Clinical Outcomes of Therapeutic Agents That Block the Platelet Glycoprotein IIb/IIIa Integrin in Ischemic Heart DiseaseCirculation, 1998
- Glycoprotein IIb/IIIa Integrin BlockadeCirculation, 1998